Two of our analysts debate who will win the US election and what that means for markets…
In a world where dividend are under unprecedented pressure, our income focused online event in September should provide serious food for thought…
Tech has beaten almost everything hands down – but nothing lasts forever. Where else should investors be looking for secular growth themes?
IBT offers a differentiated exposure to a secular growth theme complemented by a solid yield…
We discuss the opportunity as biotech stocks trade at record low valuations, despite strong prospects for the sector...
Chairman of International Biotechnology Trust, John Aston, explains how his unusual background in both biotechnology and banking come together on the trust...
Two years after the shock election of Donald Trump, we take a look at what the Trump administration has really meant for US markets and the trusts that invest in them...
Five years on from the appointment of a new manager, this US-focused biotech trust has seen its fortunes transformed...
We scour the investment trust universe for trusts offering chunky yields on a discount...
A well-resourced biotechnology fund that has produced annualised returns of +18% under the current manager, offering a yield of 4%...
Searching for the Tesla of tomorrow…
As equity valuations continue to defy logic, we identify the trusts least correlated to their fortunes...
Proven alpha generation from a strong management team, low correlation to mainstream equities, and a yield of 4%...
